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We examined the effect of central cholinergic depletion on the sedative potency of propofol in
rats. Depletion was produced by intracerebroventricular administration of an immunotoxin
speci®c to cholinergic neurones (192 IgG-Saporin; 2 mg). As a result of this lesion, acetylcholine
concentration was reduced by about 40% in the frontoparietal cortex and in the hippocampus
but was essentially normal in the striatum and cerebellum. Sedation in rats was assessed as the
decrease in locomotor activity. Sedative potency of propofol (30 mg kg±1 i.p.) was reduced by
about 50% in rats who received the injection of 192 IgG-Saporin as compared to controls.
These results show that a central cholinergic depletion alleviates the sedative effect of propo-
fol, and indicates that basal forebrain cholinergic neurones might mediate part of the sedative/
hypnotic effects of propofol.
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The cholinergic system is one of the most important
modulatory neurotransmitter systems in the brain, and has
long been recognized as playing a key role in the regulation
of consciousness.1 2 Brie¯y, the cholinergic system is
distributed in a variety of different nuclei of which two
groups (basal-forebrain and pedunculopontine) have exten-
sive projections to the cortex and thalamus.
Pedunculopontine cholinergic neurones are considered to
control rapid eye movement sleep or dreaming, while basal-
forebrain cholinergic pathways appear to generate and
integrate conscious awareness.
Cellular and molecular studies suggest that cholinergic
neurotransmission is a potential mediator of general anaes-
thetic actions.3±5 It has been largely suggested that some
anaesthetics produce their effects via actions on both
muscarinic and nicotinic receptors. In this respect, propofol
(2,6-diisopropylphenol), an intravenous general anaesthetic,
has been shown to directly act on nicotinic acetylcholine
receptors, more precisely on the subtype of nicotinic
receptors found in the central nervous system (a4b2).6±8
Propofol also has dose-dependent inhibitory effects on
acetylcholine release in the frontal cortex and hippocampus,
as shown by in vivo microdialysis in the rat brain.9 10
Though there are some reports of the effects of propofol on
cholinergic neurotransmission, to date there is no clinical
and/or physiological evidence that an inhibitory effect on
cholinergic function may be involved in the sedative/
hypnotic effects of propofol.
To what extent cholinergic neurons mediate the hypnotic
effects of propofol, is of particular relevance to the effects of
anaesthetics in aged patients. There is evidence for an
impairment of cholinergic function in normal as well as in
neuropathological ageing,11±14 but little is known about any
age-related modi®cation of anaesthetic effects in the central
nervous system.10 Thus an investigation of the interactions
between anaesthetics and cholinergic lesions seems worth-
while, particularly if one considers the effects of anaes-
thetics may depend upon age.
We therefore wondered to what extent the cholinergic
system may be involved in propofol-induced sedative/
hypnotic effects. To address this question, we assessed the
effect of central cholinergic depletion on the sedative effect
of propofol in rats. Cholinergic depletion was performed by
intracerebroventricular (ICV) administration of 192 IgG-
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Saporin, a monoclonal antibody to the p75NGF receptor
coupled to the ribosomal toxin saporin. This neurotoxin is
selective for cholinergic neurons of the basal forebrain.15±19
Using a locomotor activity test, we measured the sedative
potency of propofol in lesioned rats as compared to controls.
The extent of the cholinergic damage was assessed by
measuring acetylcholine concentrations in various regions
of the brain.
Methods
All procedures involving animals and their care were
conducted in accordance with the institutional guidelines
that are in compliance with national (concil directive
#87848, October 19, 1987, MinisteÁre de l'Agriculture et
de la ForeÃt, Service VeÂteÂrinaire de la SanteÂ et de la
Protection Animales; permission #6212 to J-C. Cassel) and
international (NIH publication, N°86±23, revised 1985)
laws and policies.
Materials
Animals
We used 16 female Long Evans rats (Janvier, France) that
weighed 200±210 g. They were housed in a colony room
maintained on a 12:12 h dark-light cycle (lights on at 7:00
AM), with food and water provided ad libitum. The colony
and testing rooms were temperature controlled (21°C).
Drugs
Propofol (10 mg ml±1, Diprivan; Zeneca, Paris, France) was
dissolved in 10% intralipid. Drugs were prepared immedi-
ately before use and injected intraperitoneally (i.p.) in a
volume of 3 ml kg±1.
Apparatus
Eight identical activity cages (size, 45 3 30 330 cm) were
used. Each cage had an infrared detector (IPR124, Talco,
Paris, France) placed behind a Fresnel lens and located at
the roof of the cage, which allows monitoring of animal
movement in different sections of the cage. The signal was
fed into a computer that summed all horizontal movements
(one unit representing one crossing from one section to the
other) during three consecutive periods of 5 min.
Study design
Rats were randomly allocated to two groups as follows: rats
with saporin lesions (SAPO; n=8) and sham-operated
controls (SHAM; n=8). During surgery, the rats received
ICV infusions of 192 IgG-Saporin to induce a cholinergic
depletion (SAPO), or vehicle (SHAM). The sedative effect
of propofol (30 mg kg±1, intraperitoneally) was measured
using a crossover behavioural experiment that measured
locomotor activity. Finally the extent of the cholinergic
depletion was assessed neurochemically by determining the
concentration of acetylcholine in the frontoparietal cortex,
hippocampus, striatum and cerebellum.
Surgery
All surgical procedures19 were conducted under aseptic
conditions, using equitesin (composed of pentobarbital,
chloral hydrate and alcohols) anaesthesia (3.0 ml kg±1, i.p.).
Following a mini-craniotomy, injections into the lateral
ventricles were performed stereotaxically using a 2-ml
Hamilton syringe at the following co-ordinates (in mm): A:
±0.8 (from Bregma), L: 61.4 (from midline); V: ±4.3 (from
Bregma), with the incisor bar set at the level of the interaural
line. Following injection, the needle was left in situ for 5
min, retracted over 2 mm, and maintained there for another
4 min before complete retraction. Rats with saporin lesions
received an ICV injection of 2 mg of the immunotoxin 192
IgG-Saporin (2 mg per rat; 1 ml per lateral ventricle,
concentration 1 mg ml±1 of phosphate-buffered saline). In the
control group, rats were treated in a similar manner, except
that phosphate-buffered saline was injected in place of 192
IgG-Saporin.
Behavioural experiment
Propofol-induced sedation was assessed as follows:20 21 the
rat was placed in an activity cage with its horizontal
movements being recorded using a detector located at the
top of the cage. When placed in such a cage, undrugged rats
exhibited a locomotor activity aimed at exploring which
decreased progressively over time. Activity counts ex-
pressed as metric units explored per 5 min were used as
activity scores. The experiment was performed over 2 days.
The ®rst day, half the rats of each group were injected
intraperitoneally with propofol (30 mg kg±1), the remainder
injected with vehicle. All rats were then returned to their
home cage. Ten minutes later, each rat was placed in one of
the eight experimental cages and tested for 15 min. During
the test, locomotor activity was recorded during three
consecutive periods of 5 min, abbreviated T1, T2 and T3
hereafter. The second day, the procedure was reversed
(vehicle instead of propofol, and vice versa).
Comparison of the activity scores found after the
injection of vehicle in rats with saporin lesions with those
of sham-operated controls allowed assessment of the effect
of the cholinergic lesion. Comparison of the activity scores
found after propofol injection with those after vehicle
allowed determination ofthe effects of the cholinergic lesion
on the sedative potency of propofol. Sedative potency was
calculated for each rat as follows: (activity score after
vehicle injection minus activity score after propofol injec-
tion)/(activity score after vehicle injection plus activity
score after propofol injection).
Neurochemical control
To control for the ef®ciency of the cholinergic lesions, six
rats of each group (SHAM or SAPO) were arbitrarily chosen
by an experimenter who was unaware of the rats' activity
scores. These were killed by microwave irradiation in order
to inactivate brain enzymes such as acetylcholinesterase.
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Following decapitation, the brain was extracted and dis-
sected on a cold plate in order to separate the striatum,
frontoparietal cortex, and hippocampus. The hippocampus
was further split into its dorsal and ventral areas. Left and
right structures from each rat were pooled, weighed and
maintained at ±80°C until neurochemical determination.
To determine acetylcholine concentrations by high
performance liquid chromatographic analysis, tissue
samples were homogenized in 1 N formic acid/acetone
(18/8.5, vol./vol.). Formic extracts were then puri®ed by
a tetraphenylboron exchange of amines in 3-heptanone,
followed by 0.1 N HCl extraction. High performance
liquid chromatographic analysis was performed on a
C(18)Spherisorb ODS2 reverse phase column (3 mm
pore size, 7 mm in diameter, 10 cm long). The mobile
phase consisted of 0.05 M KH2PO4, pH=7, containing
600 mg litre±1 of tetramethylammonium chloride and 25
mg litre±1 sodium octane sulphate. The ¯ow rate was
0.8 ml min±1. Acetylcholine was converted into betaine
in a post-column reactor with covalently bound acet-
ylcholinesterase and choline oxidase. The resulting
hydrogen peroxide was detected using a 50740 ESA
cell working electrode at 0.3 V.
Statistical analysis
For behavioural experiments, two dependent variables
were used: activity score after vehicle injection and
sedative potency of propofol. Statistical analyses of
these variables were performed using analysis of vari-
ance with repeated measures (between factor: SHAM or
SAPO, within factor: time). For neurochemical control,
one way analyses of variance as performed on
acetylcholine concentration in the different brain struc-
tures, namely hippocampus (dorsal and ventral), fronto-
parietal cortex, striatum and cerebellum. P<0.05 was
considered indicative of statistical signi®cance.
Results
Following injection of vehicle alone, the absolute activity
scores decreased progressively in both groups during the
test (activity scores, mean (SEM); T1: 306 (20) vs. 278 (12);
T2: 240 (21) vs. 249 (24); T3: 189 (15) vs. 193 (24), for
groups SHAM and SAPO, respectively). Analysis of
variance showed a signi®cant effect of the Time (P<0.05),
but no effect of Group, SHAM or SAPO (P=0.83).
The sedative potency of propofol (30 mg kg±1 i.p.) was
signi®cantly decreased in SAPO, as compared to SHAM
rats (Figure 1). The time course of the sedative effect
appeared similar in both groups. Analysis of variance
showed a signi®cant effect of Group, SAPO or SHAM, but
no statistical signi®cant effect of Time nor interaction
between Group and Time (Group, P<0.05; Time, P=0.07;
Group3Time, P=0.67).
Acetylcholine concentrations were signi®cantly reduced
in the frontoparietal cortex and hippocampus for SAPO, as
compared to SHAM rats (all P<0.05) (Table 1).
Acetylcholine concentrations in the striatum and cerebellum
were not signi®cantly altered by 192 IgG-Saporin (striatum,
P=0.62; cerebellum, P=0.68).
Discussion
In the present study we report for the ®rst time that
cholinergic neurotransmission may be involved in the
sedative effects of propofol.
To our knowledge, we show for the ®rst time that
cholinergic depletion in the basal forebrain alleviates the
sedative effect of propofol in rats. Indeed, the activity found
after propofol treatment was signi®cantly less in rats which
had sustained ICV injection of 192 IgG-Saporin than in
controls. Sedative potency of propofol was decreased by
about 50% but the time-course of the sedative effect
appeared unchanged (Fig. 1). This ®nding cannot be
attributed to the pre-existence of impaired locomotion due
to 192 IgG-Saporin, as the activity scores following
injection of vehicle were comparable in the experimental
and control groups. Evidence that 192 IgG-Saporin induced
cholinergic depletion in the basal forebrain is substantiated
by reduced acetylcholine concentration in the hippocampus
and frontoparietal cortex (Table 1). From previous experi-
ments using intraventricular administration of 192 IgG-
Saporin, it is known that the extent of cholinergic depletion
depends on the amount of 192 IgG-Saporin injected. Close-
to-maximum effects are generally obtained with about 5
mg.22 In our study, the reduction of acetylcholine concen-
tration was about 40%. Importantly for locomotion and
movement, the concentration of acetylcholine in the
striatum was unchanged, an observation which is in line
Fig 1 Sedative potency of propofol 30 mg kg±1 i.p. (T1: 10±15 min, T2:
15±20 min, T3: 20±25 min, after the injection) in rats who received
intraventricular injections of 2 mg of 192 IgG-Saporin (SAPO) or of 2 ml
of phosphate-buffered saline solution (SHAM). Sedative potency was
expressed as the ratio: (activity score after vehicle injection minus
activity score after propofol injection)/(activity score after vehicle
injection plus activity score after propofol injection). Results are
expressed as mean6SEM.
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with previous reports.22 23 Similarly, the concentration of
acetylcholine in the cerebellum was not signi®cantly
affected by 192 IgG-Saporin.
How might a depletion of basal forebrain cholinergic
neurons alleviate the depressant effect of propofol on the
central nervous system? Physiological studies have high-
lighted the role of cholinergic neurotransmission in the
maintenance of consciousness.1 2 Depending on the brain
area, cholinergic neurotransmission exerts either an ex-
citatory or an inhibitory role on consciousness. For example,
small amounts of acetylcholine injected into the tegmental
reticular formation cause sleep whereas infusions of
acetylcholine in the region of the amygdala, septum or
hippocampus stimulate arousal behaviour.24 From our
results, it is clear that the basal forebrain cholinergic system
participates in propofol-induced sedation although its
alteration has no major effect on exploratory activity in
our experimental conditions. We suggest that propofol
depresses central nervous system excitability by a mechan-
ism that probably involves, at least in part, inhibition of the
excitatory effect of the basal forebrain cholinergic system
associated with the maintenance of consciousness.
However, it is generally accepted that propofol acts as a
potent gamma-aminobutyric acid (GABA) agonist.
Propofol potentiates the inhibitory actions of the GABAA
receptor and its pharmacological mechanisms have been
investigated in some detail.25±27 Using in vivo microdia-
lysis, Kikuchi et al.9 have shown that the inhibitory effects
of propofol on acetylcholine release is mediated by GABAA
receptors in the frontal cortex and in the hippocampus in
rats. Because propofol acts directly on ligand-gated ion
channels of GABAA and neuronal nicotinic receptors, the
mechanisms by which the hypnotic effects of propofol occur
may involve an inhibition of speci®c neuronal acetylcholine
receptors in addition to an interaction with GABAA
receptors implicated in the modulation of the activity of
cholinergic neurons.
The interaction between propofol and central cholinergic
function is of great interest in investigations of the
mechanisms which underlie the age-dependent effects of
propofol. Recent experimental studies showed that brain
sensitivity to propofol can be modi®ed by ageing.10 28 29 In
particular, the anaesthetic potency of propofol appears
reduced by ageing, independently of any pharmacokinetic
modi®cations. Larsson and Wahlstrom29 demonstrated that
brain concentrations of propofol need to be increased in
aged as compared to young rats, in order to obtain the same
depressant effect of propofol on electroencephalographic
parameters. As previously mentioned, central cholinergic
function is impaired by normal ageing.11±14 For example, in
the aged brain cholinergic markers such as the activity of
choline acetyltransferase and the levels of hemicolinium-3
binding are reduced in the medial septum, the hippocampus
and the cingulate cortex.13 Similarly, the biosynthesis of
nicotinic receptors is reduced by ageing as shown by a
30±50% reduction of mRNA levels in the brain of 29- to 32-
month-old rats.12 Because ageing alters cholinergic function
and in the light of our present ®ndings, one could
hypothesise that the weaker potency of propofol to induce
sedative/hypnotic effects in the aged subjects is due to the
alteration of cholinergic function.
In summary, our study shows that the sedative effect of
propofol is partly mediated by cholinergic mechanisms and
can be attenuated by an alteration of cholinergic function in
the basal forebrain. This ®nding points towards a key role of
cholinergic mechanisms in the effects of propofol.
Moreover, our results support the working hypothesis that
the ageing process might reduce the brain sensitivity to
propofol due to age-related changes in cholinergic function.
To what extent this could apply to the anaesthetic effect of
propofol or of other anaesthetics needs further investigation.
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